NewEdge Advisors’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $991K | Buy |
2,760
+51
| +2% | +$15.6K | ﹤0.01% | 1669 |
|
|
2026
Q1 | $679K | Sell |
2,709
-385
| -12% | -$95.8K | ﹤0.01% | 1758 |
|
|
2025
Q4 | $851K | Sell |
3,094
-849
| -22% | -$232K | ﹤0.01% | 1589 |
|
|
2025
Q3 | $1.03M | Sell |
3,943
-20,484
| -84% | -$4.98M | ﹤0.01% | 1386 |
|
|
2025
Q2 | $5.34M | Buy |
24,427
+3,772
| +18% | +$806K | 0.03% | 546 |
|
|
2025
Q1 | $4.62M | Buy |
20,655
+3,554
| +21% | +$979K | 0.03% | 530 |
|
|
2024
Q4 | $5.6M | Buy |
17,101
+1,145
| +7% | +$360K | 0.03% | 461 |
|
|
2024
Q3 | $4.79M | Buy |
15,956
+13,503
| +550% | +$4.14M | 0.03% | 490 |
|
|
2024
Q2 | $808K | Buy |
2,453
+114
| +5% | +$40.3K | 0.01% | 1166 |
|
|
2024
Q1 | $926K | Sell |
2,339
-4,585
| -66% | -$1.7M | 0.01% | 1041 |
|
|
2023
Q4 | $2.44M | Sell |
6,924
-455
| -6% | -$161K | 0.02% | 598 |
|
|
2023
Q3 | $2.77M | Buy |
7,379
+2,636
| +56% | +$1.02M | 0.03% | 484 |
|
|
2023
Q2 | $1.81M | Buy |
4,743
+3,688
| +350% | +$1.32M | 0.02% | 622 |
|
|
2023
Q1 | $379K | Buy |
1,055
+154
| +17% | +$45K | ﹤0.01% | 1245 |
|
|
2022
Q4 | $45.6K | Sell |
901
-5,621
| -86% | -$1.33M | ﹤0.01% | 1756 |
|
|
2022
Q3 | $1.6M | Buy |
6,522
+770
| +13% | +$235K | 0.03% | 484 |
|
|
2022
Q2 | $1.74M | Buy |
+5,752
| New | +$1.87M | 0.03% | 476 |
|
|
2022
Q1 | – | Sell |
-10,033
| Closed | -$4.71M | – | 1665 |
|
|
2021
Q4 | $4.71M | Buy |
10,033
+3,746
| +60% | +$1.61M | 0.07% | 257 |
|
|
2021
Q3 | $2.67M | Buy |
6,287
+195
| +3% | +$82.2K | 0.07% | 265 |
|
|
2021
Q2 | $2.19M | Buy |
6,092
+502
| +9% | +$166K | 0.06% | 285 |
|
|
2021
Q1 | $1.57M | Sell |
5,590
-328
| -6% | -$93.9K | 0.05% | 336 |
|
|
2020
Q4 | $1.68M | Buy |
5,918
+375
| +7% | +$105K | 0.06% | 291 |
|
|
2020
Q3 | $1.52M | Buy |
5,543
+2,388
| +76% | +$632K | 0.05% | 292 |
|
|
2020
Q2 | $717K | Sell |
3,155
-222
| -7% | -$43.6K | 0.03% | 445 |
|
|
2020
Q1 | $514K | Buy |
3,377
+849
| +34% | +$131K | 0.02% | 442 |
|
|
2019
Q4 | $380K | Sell |
2,528
-92
| -4% | -$13.4K | 0.02% | 600 |
|
|
2019
Q3 | $372K | Buy |
2,620
+64
| +3% | +$8.81K | 0.02% | 582 |
|
|
2019
Q2 | $320K | Buy |
2,556
+10
| +0.4% | +$1.18K | 0.02% | 511 |
|
|
2019
Q1 | $281K | Buy |
2,546
+241
| +10% | +$25.1K | 0.02% | 544 |
|
|
2018
Q4 | $226K | Buy |
2,305
+52
| +2% | +$5.64K | 0.01% | 564 |
|
|
2018
Q3 | $278K | Buy |
+2,253
| New | +$253K | 0.02% | 517 |
|
|
2017
Q3 | – | Sell |
-175
| Closed | -$16.3K | – | 1133 |
|
|
2017
Q2 | $16.3K | Buy |
+175
| New | +$16.1K | ﹤0.01% | 799 |
|
Other funds holding WST
GIM
NewEdge Advisors's WST Position: Q2 2026 in Review
NewEdge Advisors increased its West Pharmaceutical (WST) stake by 1.9% in Q2 2026, buying an estimated $15.6K and bringing the position to 2,760 shares worth $991K. The position accounts for ﹤0.01% of the portfolio, ranked #1669.
NewEdge Advisors first reported a position in WST in Q2 2017 and has held it in 32 quarters since. The position peaked at $5.6M in Q4 2024. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.
- NewEdge Advisors held 2,760 shares of West Pharmaceutical worth $991K as of Q2 2026.
- NewEdge Advisors bought 51 West Pharmaceutical shares in Q2 2026, an estimated $15.6K.
- West Pharmaceutical made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #1669 holding.
- NewEdge Advisors first reported a position in West Pharmaceutical in Q2 2017 and has held it in 32 quarters since.
- NewEdge Advisors's West Pharmaceutical position peaked at $5.6M in Q4 2024.
- 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.
Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.